Berlin - Delayed Quote • EUR
Laboratorios Farmaceuticos Rovi SA (41L.BE)
At close: April 24 at 8:12 AM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
113,247.00
113,247.00
237,602.00
149,441.00
46,876.00
Investing Cash Flow
-52,028.00
-52,028.00
-57,154.00
-40,839.00
-39,625.00
Financing Cash Flow
-160,842.00
-160,842.00
-154,538.00
-62,729.00
-21,515.00
End Cash Position
25,322.00
25,322.00
124,945.00
99,035.00
53,162.00
Capital Expenditure
-55,187.00
-55,187.00
-51,388.00
-40,940.00
-39,692.00
Issuance of Capital Stock
52,639.00
52,639.00
77,766.00
42,328.00
37,488.00
Issuance of Debt
734.00
734.00
1,399.00
1,340.00
1,430.00
Repayment of Debt
-13,654.00
-13,654.00
-6,768.00
-6,192.00
-13,179.00
Repurchase of Capital Stock
-133,900.00
-133,900.00
-177,008.00
-78,785.00
-37,255.00
Free Cash Flow
58,060.00
58,060.00
186,214.00
108,501.00
7,184.00
12/31/2020 - 12/6/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade